PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of sjgastroHomeCurrent IssueInstructionsSubmit article
 
Saudi J Gastroenterol. 2010 July; 16(3): 145–153.
PMCID: PMC3003209

Cardiovascular Changes in Cirrhosis: Pathogenesis and Clinical Implications

Abstract

Liver cirrhosis is associated with a wide range of cardiovascular abnormalities including hyperdynamic circulation, cirrhotic cardiomyopathy, and pulmonary vascular abnormalities. The pathogenic mechanisms of these cardiovascular changes are multifactorial and include neurohumoral and vascular dysregulations. Accumulating evidence suggests that cirrhosis-related cardiovascular abnormalities play a major role in the pathogenesis of multiple life-threatening complications including hepatorenal syndrome, ascites, spontaneous bacterial peritonitis, gastroesophageal varices, and hepatopulmonary syndrome. Treatment targeting the circulatory dysfunction in these patients may improve the short-term prognosis while awaiting liver transplantation. Careful fluid management in the immediate post-transplant period is extremely important to avoid cardiac-related complications. Liver transplantation results in correction of portal hypertension and reversal of all the pathophysiological mechanisms that lead to the cardiovascular abnormalities, resulting in restoration of a normal circulation. The following is a review of the pathogenesis and clinical implications of the cardiovascular changes in cirrhosis.

Keywords: Cirrhosis, cirrhotic cardiomyopathy, hyperdynamic circulation, liver transplantation

Patients with end-stage liver disease manifest a hyperdynamic circulation characterized by a decrease in the systemic vascular resistance and arterial pressure, and an increase in the heart rate and cardiac output. The clinical manifestations of hyperdynamic circulations include warm skin, spider angioma, palmer erythema, and bounding pulse. These cardiovascular changes were described over 50 years ago by Kowalski and Abelmann in a group of alcoholic cirrhotic patients.[1] These findings were then confirmed in multiple experimental models of portal hypertension and in patients with cirrhosis. Initially it was thought that these changes were a manifestation of latent alcoholic cardiomyopathy, however future studies confirmed the same circulatory dysregulation in cirrhotic patients with different underlying diseases.[24]

Different pathophysiological mechanisms including neurogenic, humoral, and vascular dysregulations are implicated in the pathogenesis of these cardiovascular changes. The hyperdynamic circulation is most likely initiated by splanchnic and peripheral vasodilatation, leading to reduction in the effective arterial blood volume. This leads to a diminished renal blood flow in cirrhotic patients, which in turn stimulates the rennin-angiotensin-aldesterone system (RAAS), sympathetic nervous system, and antidiuretic hormone resulting in renal artery vasoconstriction, sodium retention, and volume expansion.[5] Worsening liver disease results in progressive vasodilatation, making the hyperdynamic circulation and renal artery vasconstriction more pronounced.[67]

These circulatory changes lead to the development of multiple life-threatening complications including hepatorenal syndrome (HRS), ascites, spontaneous bacterial peritonitis (SBP), gastroesophageal varices, and hepatopulmonary syndrome.

The following is a review of the pathogenesis and clinical implications of the cardiovascular changes in cirrhosis.

SYSTEMIC AND SPLANCHNIC CIRCULATION IN CIRRHOSIS

Arterial vasodilatation is regulated by complex interactions of different vasodilator molecules. Cirrhosis leads to portal hypertension which induces portosystemic collaterals, allowing gut-derived humoral substances to directly enter the systemic circulation without detoxification by the liver. In recent years, nitric oxide (NO) has been recognized as the most important vasodilator molecule in the splanchnic and systemic circulation. NO is overproduced in cirrhosis; measured serum levels are significantly elevated in both cirrhotic patients and in animal models.[810] NO is an endothelial-derived relaxing factor that leads to arterial vasodilatation. Its distribution differs in the splanchnic circulation; the intrahepatic microcirculation is altered significantly in liver cirrhosis, secondary to both architectural and vasoactive humoral changes, resulting in an increase in vasoactive molecules including angiotensin II, endothelin 1, and cysteinylleukotrienes associated with a decrease in intrahepatic NO production. The net result is a progressive increase in intrahepatic vascular resistance and subsequently portal hypertension. On the other hand, NO overproduction has been clearly documented in the remaining part of the splanchnic circulation in patients with cirrhosis. This is thought to be related to the altered intestinal mucosal permeability in cirrhotic patients, leading to the transfer of different endotoxins across the intestinal membrane to the systemic circulation. These endotoxins promote NO production.[11,12] Cytokines including TNF-α are among other factors that are considered to be NO inducers, whose effect has been demonstrated in a number of animal model studies.[1315] Inhibition of TNF-α production or the blocking of TNF-α mediated signaling by TNF-α antibodies, resulted in normalization of NO production in experimental studies, which in turn leads to an improvement in the hyperdynamic circulation.[14,15]

Three isoforms of NO synthase (NOS) have been described: endothelial (eNOS), inducible (iNOS), and neuronal (nNOS). However, the leading isoform contributing to these vascular changes remains obscure. Multiple studies using nonspecific NOS inhibitors revealed that diminishing NO production resulted in normalization of the peripheral vascular vasodilatation.[16] Ferguson et al demonstrated that the selective inhibition of iNOS causes peripheral vasoconstriction in patients with cirrhosis but not in healthy-matched controls, suggesting the contribution of NOS in the regulation of peripheral vascular tone and the hyperdynamic circulation of end stage liver disease.[17] Other studies favor eNOS as the leading source of the vascular NO overproduction in the splanchnic arterial circulation.[1819]

Other agents that are thought to play a role in the peripheral vasodilatation of cirrhosis include endocannabinoids.[20] They are lipid-like substances that act on two inhibitory G protein-coupled receptors, CB1 and CB2. CB1 receptors are upregulated in the vascular endothelium of cirrhotic rats in association with an increase in endocacannabinoids monocyte production. Activation of endothelial cannabinoid 1 (CB1) receptors by the endogenously produced endocannabinoids causes pronounced vasodilatation in the cirrhotic rats.[21]

More recently, multiple studies have shown a potentially important role of the central nervous system in the pathogenesis of the portal hypertension-induced hyperdynamic circulation.[2225] Liu et al, demonstrated that primary afferent denervation by capsaicin, reversed the hyperdynamic circulation in cirrhotic rats. These findings suugest that primary afferent nerves may be the signaling pathway from the periphery to the CNS. Detection of a marker protein (Fos) in the brainstem and hypothalamic cardiovascular-regulatory nuclei of rats, immediately following portal vien ligation, indicates CNS activation. This is followed by hyperdynamic circulation, suggesting that the CNS activation plays a role in the pathogenesis of the hyperdynamic circulation. Additionally, blocking CNS Fos expression in cirrhotic rats resulted in eliminating the development of the hyperdynamic circulation.[25]

THE HEART (CIRRHOTIC CARDIOMYOPATHY)

In addition to the hyperdynamic circulation, impaired ventricular contractility in response to stimuli was also described in cirrhotic patients.[2627] Initially, this was thought to be a manifestation of latent alcoholic cardiomiopathy but later studies in non-alcoholic patients and in experimental animal models revealed the same pattern of blunted cardiac contractile responsiveness.[28,29] Thus, these cardiovascular changes are now termed “cirrhotic cardiomyopathy.”[3,4] Due to the associated systemic vasodilatation, overt heart failure is generally not a feature of cirrhotic cardiomyopathy.

In the absence of specific diagnostic criteria, the exact prevalence of cirrhotic cardiomyopathy remains unclear. The characteristic features of cirrhotic cardiomyopathy include (a) an attenuated systolic or diastolic response to stress stimuli, (b) structural or histological changes in cardiac chambers, (c) electrophysiological abnormalities, and (d) serum markers suggestive of cardiac stress.

The impaired cardiovascular responsiveness in cirrhosis is likely related to a combination of factors that include cardiomyocyte plasma membrane physicochemical changes, attenuated stimulatory pathways, and enhanced activity of inhibitory systems which includes the following:

  1. β -adrenergic receptor function: The role of β-adrenergic receptors was examined in multiple studies. Heart cell contractility is mainly determined by the stimulatory β-adrenergic receptor system.[30] This system consists of the receptor, heterotrimeric guanine nucleotide-binding proteins (G-proteins), and adenylate cyclase. Catecholamine stimulation of the β-adrenoceptor leads to a number of interactions resulting in the production of the second messenger, cAMP. cAMP is the primary trigger that leads to intracellular calcium fluxes and cardiac muscle contraction.[3132] Several studies examined this pathway in cirrhotic patients and animal models. β-adrenergic receptor density in cirrhotic patients and animal models were reduced.[28] Ma et al. found that β-adrenoceptors signaling pathway is also impaired at different levels, starting with decreased membrane content and function of the stimulatory Gs-protein and ending up with impaired activity of the adenylate cyclase enzyme itself.[3334]
  2. Muscarinic receptor activity: Muscarinic responsiveness was found to be blunted in cirrhotic hearts.[35] Muscarinic receptor stimulation exerts a negative inotropic effect on cardiac muscle counterbalancing the stimulatory β-adrenergic system. Thus, an enhanced muscarinic tone could contribute to the pathogenesis of negative inotropic effects on the myocardium.
  3. Membrane fluidity: Membrane fluidity is a term used to describe the degree of motional freedom for lipid moieties in the lipid bilayer of the plasma membrane.[36] It has been demonstrated that the fluidity of the plasma membranes from heart cells and other tissues is decreased in cirrhotic patients, impairing the physiological function of the tissue biomembranes.[34,36] These changes have a profound effect on the β-adrenoceptor function that includes impairing the receptor-ligand interaction, receptor density, and intracellular signaling pathway. Restoration of normal values of membrane fluidity in an animal model resulted in a significant improvement in the function of β-adrenoceptors.[33]
    Altered membrane fluidity also affects the function of membrane-bound ion channels. Moreau et al. have shown altered control of vascular tone by Ca++ and K+ channels. In their study, potassium channel blockers resulted in a significant increase in the vascular tone in cirrhotic rats compared to normal rats.[37,38] Another study showed a decrease in the function of two types of K+ channels in ventricular myocytes from cirrhotic rats, which could potentially explain the prolongation of the QT interval.[39] Additionally, the movement of calcium into the cell is altered affecting cardiomyocyte contraction. Calcium enters the cell through membrane calcium channels, and is stored and released from the sarcoplasmic reticulum intracellular stores. The calcium channel dysfunction leading to decreased cardiomyocyte contractility was also demonstrated in an animal model study.
  4. Nitric oxide: NO plays an important role in regulating the systemic and coronary vascular tone and its effect has been implicated in the pathogenesis of different cardiac dysfunctions including ischemic heart disease.[40,41] Non-selective blockade of nitric oxide synthase (NOS) by N omega-monomethyl-L-arginine (L-NMMA) augments the contractile response of rat ventricular myocytes to the β-agonist isoproterenol without any effect on the baseline contractility, suggesting the inhibitory effect of NO on cardiac contractility.[42] Similarly, in another study, inhibition of NO synthesis with L-NMMA restored the blunted contractility function of isolated hearts from cirrhotic rats, while it had no significant effect on the animals in the control group.[43]
  5. Carbon monoxide (CO): CO is a known vasodilator that also exerts a negative effect on cardiac contractility through cGMP.[44] CO stimulates guanylate cyclase to produce cyclic guanosine monophosphate (cGMP), which phosphorylates protein kinase G and inhibits calcium influx into the cytosol of the cardiomyocyte. Lui et al. investigated its role in the pathogenesis of cirrhotic cardiomyopathy. They showed that HO-1 mRNA transcription and protein expression are significantly augmented in ventricles of cirrhotic animals compared to controls. They also showed that the hemeoxygenase inhibition significantly decreased the elevated cGMP content and reversed the decreased contractility of isolated BDL papillary muscles with no affect on control muscles.[45] Based on these findings, they suggested that activation of the HO/CO pathway is involved in the pathogenesis of cirrhotic cardiomyopathy.
  6. Endocannabinoids: Upregulation of the cannabinoid signaling pathway has been described in chronic liver disease.[21] Endogenous cannabinoids exert a negative inotropic effect in human and animal models through their interaction with the inhibitory G-protein-coupled receptors, CBI and CB2, leading to the inhibition of adenylate cyclase activity and calcium influx into the cytosol of the cardiomyocyte.[46,47] Gaskari et al. showed that the blunted contractile response of isolated left ventricular papillary muscle from cirrhotic rats is restored after preincubation with a CB1 antagonist.[48]

Clinical implications

This circulatory dysfunction characterized by arterial vasodilatation and an increase in cardiac output is the proposed pathophysiological mechanism leading to sodium and water retention in patients with liver cirrhosis.[49] Initially the decrease in systemic vascular resistance is compensated by the development of a hyperdynamic circulation. However, with disease progression, the extreme extension of these hemodynamic changes leads to severe renal vasoconstriction and a decline in renal function which characterizes the HRS.[50,51] The development of hepatorenal syndrome in this setting is also associated with a drop in the cardiac output, emphasizing the additional role of cirrhotic cardiomyopathy in the pathogenesis of hepatorenal dysfunction. A recent study compared the hemodynamic changes in relation to sodium intake of 22 mmol/day between 35 cirrhotic patients, with or without ascites, and a group of healthy controls. After subjecting 14 patients with non-ascitic cirrhosis and 8 controls to a sodium load of 200 mmol/day for 7 days, they showed that patients with non-ascitic cirrhosis had cardiac contractile dysfunction which was augmented by the dietary sodium load and was also associated with significant sodium retention compared to the healthy controls.[52] Another study assessed the relationship between the development of HRS and cardiac dysfunction in a cohort of patients with SBP. They They demonstrated that patients who developed acute renal failure had a significantly less cardiac reserve, manifested by a lower cardiac output and a higher systemic vascular resistance at admission and following the treatment of the spontaneous bacterial peritonitis, when compared to patients who did not develop renal failure.[5354]

Several indicators of poor prognosis in liver cirrhosis are those which occur in association with extreme peripheral arterial vasodilatation, including a low mean arterial blood pressure, portal hypertension, and the elevation of different neuroendocrinal substances. Thus, treatment targeting the circulatory dysfunction in these patients may improve the short-term prognosis while awaiting liver transplantation.[5557] A recent study conducted by Esrailian et al. revealed that octerotide and midodrine therapy significantly improved renal function and 30 day survival in patients with type 1 hepatorenal syndrome.[58]

Transjugular intrahepatic portosystemic shunt (TIPS) insertion in cirrhotic patients leads to significant hemodynamic changes. TIPS causes a sudden increase in the preload in patients who are manifesting a hyperdynamic circulation at the time of the shunt insertion.[5962] Multiple cardiac-related complications including arrhythmias, heart failure, myocardial ischemia, and acute pulmonary edema have been reported following TIPS insertion.[63] An increase in the right atrial pressure, pulmonary artery pressure, pulmonary vascular resistance, and pulmonary wedge pressure has been reported, reflecting the common prevalence of diastolic dysfunction in this patient population.[60,63] Predicting patients that are at a higher risk of developing cardiopulmonary complications after TIPS insertion remains difficult. A recent study assessed the utility of E/A ratio, an indicator of diastolic dysfunction, to predict ascites clearance and mortality after TIPS insertion. They found that an E/A ratio of ≤1 was predictive of slow ascites clearance (hazard ratio=7.3, 95% confidence interval=1.3-40.7, P=0.021) and death after TIPS (hazard ratio=4.7, 95% confidence interval=1.1-20.2, P=0.035).[64] These findings are in agreement with a previous study showing a higher mortality rate in patients with an E/A ratio of < 1.[65] These studies clearly demonstrate that sudden hemodynamic changes following TIPS insertion may not be tolerated by the already compromised cardiomyocytes, this emphasizes the importance of careful selection of patients prior to TIPS insertion.

The consequences of cirrhosis-related cardiovascular alterations can also be manifested at the time of transplantation. During orthotopic liver transplantation (OLT), the hyperdynamic circulation is further compromised by the effect of anesthesia, mechanical ventilation, and surgical clamping. This results in significant reduction in the preload and subsequently a reduction in the cardiac output.[66,67] Ripoll and colleagues investigated the cardiac response during liver transplantation. In their study they demonstrated that almost 25% of patients who undergo liver transplantation, show an abnormal cardiac response during the surgical procedure after reperfusion.[68]

Postoperatively, inappropriate fluid management could lead to either hypovolemia or fluid overload, which can also be a strain on the heart. Metabolic derangements in the immediate postoperative period can also impair the cardiac contractility and hence result in significant swings in the systemic hemodynamic parameters.

Hemodynamic depression caused by hypocalcemia-induced citrate intoxication from massive transfusion was reversed after the administration of CaCl2.[69] On the other hand, the systemic vasodilatation in cirrhotic patients is thought to play a protective role in preventing the development of heart failure in the setting of cirrhotic cardiomyopathy.

Cardiac complications following liver transplantation are common involving up to 70% of patients; fortunately most of these complications are subclinical.[7072] Pulmonary edema is the most common cardiovascular complication with at least 50% of these episodes developing immediately after transplantation.[67,73] Post-operative mortality from heart failure and cardiyomyopathy has been reported shortly after transplantation.[66,67] Careful fluid management in the immediate post-transplant period is extremely important to avoid cardiac-related complications. Post-operative myocardial depression, poor cardiac output, hypoxemia and mortality were associated with poor preoperative cardiac reserve.[7476] Predicting the development of postoperative cardiac complications is very difficult. Two-dimensional and dobutamine stress echocardiography were utilized to predict the development of adverse cardiac events following liver transplantation and both had a low predictive value.[73] In a recent study, Fouad et al. reviewed one hundred and ninety-seven patients to clarify the factors that may be able to predict cardiac complications following OLT, of whom 40% suffered one or more cardiac complications within 6 months of the surgery. Pulmonary edema was the most common complication occurring in 30% of patients; other complications included overt heart failure, arrhythmia, pulmonary hypertension, pericardial effusion, and cardiac thrombus formation. In this study, adverse intraoperative cardiovascular events, previous cardiac disease, and advanced liver disease as quantified by MELD score, predicted post-operative cardiac complications. Other variables including age, sex, OLT indication, body mass index, blood pressure and smoking, had a poor predictive value. Additionally, none of the pre-OLT investigations including chest X-ray, electrocardiogram, echocardiography, coronary angiopgraphy, pulmonary arterial pressure and 2-methoxy isobutyl isonitrile scan, predicted post-operative cardiac complications.[67]

THE PULMONARY CIRCULATION

Intrapulmonary vascular abnormalities consisting of pulmonary vascular dilatation, intrapulmonary shunting and a low pulmonary vascular resistance, have been described in patients with liver cirrhosis[77,78] This is thought to be related to the effect of multiple vasoactive substances including NO. Measured NO level increases in patients with cirrhosis and normalizes after liver transplantation.[7980] Pulmonary alveoli are another source of NO production in cirrhotic patients. An increase occurs in both iNOS and eNOS isoforms in alveolar macrophages and pulmonary endothelial cells of cirrhotic patients.[81,82] NO inhibition resulted in a transient improvement in the pulmonary vascular disturbance.[83,84] Other studies did not confirm the same findings, suggesting that other factors may play a significant role in the pulmonary vascular tone.[85] Despite the similar effect of these vasoactive substances on both the systemic and pulmonary circulation, other pulmonary specific related mechanisms may play a major role. Hepatopulmonary syndrome, which is one of the end results of these vascular changes, can happen in early cirrhosis, in which systemic hemodynamics are usually normal.[86,87] Additionally, hepatopulmonary syndrome is only reported in around 30% of patients with advanced cirrhosis.

Endotoxin, TNF-α, endothelin-1 (ET-1), and CO are among other factors that may contribute to the pulmonary vascular changes.[88] More recently, studies focused on the role of intravascular macrophages on the pulmonary hemodynamics. Phagocytically active pulmonary intravascular macrophages accumulate in the lungs after common bile duct ligation (CBDL) in an animal model.[8] Carter et al. demonstrated in a CBDL model that not only does the macrophage production of of NO increase, but it also has an up-regulating effect on the CO production, contributing further to the pulmonary hemodynamic changes.[9] Circulating TNF-α appears to have a significant role in the accumulation of intravascular macrophages in CBDL animal models; inhibition of TNF-α results in a decrease in the number of macrophages and improves the hepatopulmonary syndrome.[10,89] Intrapulmonary and portopulmonary shunts are among other clearly described changes in patients with liver cirrhosis that have significant clinical implications.[90,91]

Portopulmonary hypertension is another syndrome that has been associated with end-stage liver disease. Portopulmonary hypertension is less prevalent than hepatopulmonary syndrome, with an estimated prevalence of around 5%.[92,93] The pathogenesis of this syndrome remains unclear. A group of investigators believe that vasoactive substances that are normally metabolized in the healthy liver, escape the detoxification and are allowed to reach the pulmonary circulation and account for the increased pulmonary pressure.[94,95] Others believe that the portopulmonary hypertension results from high cardiac output, exposing the pulmonary vasculature to increased shear stress. As a result, some patients may respond with vasoconstriction, hypertrophy and proliferation of the pulmonary arterial endothelial cells, leading to portopulmonary hypertension.[96] A third group of investigators suggested that portopulmonary hypertension results from venous thromboembolism arising from blood clots passing through portosystemic shunts before reaching the pulmonary circulation.[97] Finally, certain genetic mutations have been linked to the development of pulmonary hypertension in different diseases.[98,99] Whether a specific genetic defect plays a role in the pathogenesis of portopulmonary hypertension remains unclear.

Clinical implications

The pulmonary vascular dilatation and the intrapulmonary shunts in patients with liver cirrhosis are the leading contributors to hypoxemia in advanced liver disease. The low pulmonary vascular resistance leads to a reduction in the intrapulmonary transit time. This leads to a decrease in the oxygen diffusion across the dilated pulmonary vessels, and has been labeled as the alveolar-capillary disequilibrium hypothesis.[100] Based on the above hypothesis, there is no true shunts and the associated hypoxemia can be improved by oxygen supplementation. Another pattern of intrapulmonary vascular dilatation, characterized by localized dilatation of parts of the pulmonary vasculature and associated with large arteriovenous shunting distant from the gas exchange units has been described. This type has a true anatomical shunting, therefore the response to oxygen supplementation is poor.[101,102] The presence of numerous intrapulmonary shunts was first described by Hoffbauer et al, following which multiple imaging studies using various molecules confirmed these findings.[103105] Despite the relatively high prevalence of hypoxemia in cirrhotic patients, it is uncommon for these patients to die of respiratory failure. However, one study compared the median and 5 year survival in two groups with and without hepatopulmonary syndrome. The two groups were matched for age, etiology, and severity of liver disease according to the Child classification and the MELD score. The patients with the hepatopulmonary syndrome had a worse median and 5 year survival.[106]

Liver transplantation is the only definitive treatment for hepatopulmonary syndrome with at least 85% of patients experiencing significant improvement or complete resolution of hypoxemia following surgery.[107] However, patients with hepatopulmonary syndrome have a higher post-transplant mortality rate when compared to patients who do not have the syndrome.[108] Previously reported post-operative complications in patients with hepatopulmonary syndrome include pulmonary hypertension, cerebral embolic hemorrhages, and prolonged mechanical ventilation.[109110]

Portopulmonary hypertension is associated with high mortality, ranging between 50-90% in 5 years. Kawut et al. compared survival in patients with potopulmonary hypertension versus idiopathic pulmonary hypertension and showed that patients with portopulmonary hypertension have a higher risk of death when compared to patients with idiopathic pulmonary hypertension.[111] Postoperative mortality is usually higher in patients with a lower cardiac reserve preoperatively. As opposed to hepatopulmonary syndrome, liver transplantation is contraindicated in patients with severe portopulmonary hypertension. Recent data suggest a perioperative mortality rate of around 70% in patients with mean pulmonary artery pressure >45 mmHg.[112,113] Patients with less severe portopulmonary hypertension may benefit vasodilator therapy to reduce the pulmonary pressures prior to transplantation.[114]

LIVER TRANSPLANTATION

Liver transplantation results in correction of portal hypertension and reversal of all the pathophysiological mechanisms that lead to hyperdynamic circulation. The effect of liver transplantation on the systemic hemodynamics has been studied by different groups. We studied the hemodynamic changes of 66 patients in the immediate postoperative period, comparing patients with viral and alcoholic cirrhosis.[115] We found that within the first 24-h of transplant, there was a significant decrease in the heart rate (HR) and an increase in the mean arterial pressure (MAP), the extent of change was similar in the two groups. The central venous and pulmonary capillary wedge pressures, and systemic vascular resistance increased, and cardiac index decreased in the viral but not the alcoholic patients. Patients with alcoholic cirrhosis showed a lower pulmonary vascular resistance and pulmonary artery pressure compared to the viral group at 24 h. Although the hyperdynamic circulation persists in the immediate post-transplant period, systemic parameters improve faster in the viral group. We also showed that pulmonary hemodynamics differ significantly between the two groups within the first 24 h, suggesting that alcoholics may have more pronounced pulmonary vasodilation than viral-cirrhotic patients. Glauser studied the systemic hemodynamics within the first 96 h following liver transplantation in 21 patients; his results suggested a progressive improvement towards normality within the study period.[116] Navasa et al. examined the hemodynamics of 12 patients at 2 weeks and 2 months following liver transplantation and suggested that most of the hemodynamic changes reverse.[117] On the other hand, other studies showed persistence of the hyperdynamic circulation for at least 6 months post transplantation.[118,119] Henderson et al. studied the cardiac output in 21 patients before and at 1 or 2 years following transplantation. They showed that the high cardiac output persist at both time periods.[118] Another study showed that the hyperdynamic circulation persists in the first 6 months following transplantation, but at 12 months the hyperdynamic circulation improves significantly.[119] The authors of these studies suggest that persistent collateral circulation may be the reason for the slow but gradual improvement of the hyperdynamic circulation. The use of different diagnostic modalities and the limited number of patients in these studies, makes it difficult to draw definite conclusions on the exact effect of transplantation on the hemodynamics.

Footnotes

Source of Support: Nil

Conflict of Interest: None declared.

REFERENCES

1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest. 1953;32:1025–33. [PMC free article] [PubMed]
2. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences. Hepatology. 1994;20:1359–63. [PubMed]
3. Ma Z, Lee SS. Cirrhotic cardiomyopathy: Getting to the heart of the matter. Hepatology. 1996;24:451–9. [PubMed]
4. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart. 2002;87:9–15. [PMC free article] [PubMed]
5. Wong F, Sniderman K, Blendis L. The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. Gastroenterology. 1998;115:397–405. [PubMed]
6. Møller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008;2:416–28. [PMC free article] [PubMed]
7. Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am. 2009;93:855–69. [PubMed]
8. Chang SW, Ohara N. Chronic biliary obstruction induces pulmonary intravascular phagocytosis and endotoxin sensitivity in rats. J Clin Invest. 1994;94:2009–19. [PMC free article] [PubMed]
9. Carter EP, Hartsfield CL, Miyazono M, Jakkula M, Morris KG, Jr, McMurtry IF. Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol. 2002;283:L346–53. [PubMed]
10. Sztrymf B, Rabiller A, Nunes H, Savale L, Lebrec D, Le Pape A, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J. 2004;23:752–8. [PubMed]
11. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol. 1987;4:8–14. [PubMed]
12. García-Tsao G. Bacterial translocation: Cause or consequence of decompensation in cirrhosis? J Hepatol. 2001;34:150–5. [PubMed]
13. Odeh M, Sabo E, Srugo I, Oliven A. Serum levels of tumor necrosis factor-alpha correlate with severity of hepatic encephalopathy due to chronic liver failure. Liver Int. 2004;24:110–6. [PubMed]
14. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: A major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 1995;108:761–7. [PubMed]
15. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 1996;23:1616–21. [PubMed]
16. Niederberger M, Martin PY, Ginès P, Morris K, Tsai P, Xu DL, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology. 1995;109:1624–30. [PubMed]
17. Ferguson JW, Dover AR, Chia S, Cruden NL, Hayes PC, Newby DE. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut. 2006;55:542–6. [PMC free article] [PubMed]
18. Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol. 1999;276:G1043–51. [PubMed]
19. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanism of extrahepatic vasodilatation in portal hypertension. Gut. 2008;57:1300–14. [PubMed]
20. Moezi L, Gaskari SA, Lee SS. Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2008;295:G649–53. [PubMed]
21. Bαtkai S, Jαrai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 2001;7:827–32. [PubMed]
22. Lee SS, Sharkey KA. Capsaicin treatment blocks development of hyperkinetic circulation in portal hypertensive and cirrhotic rats. Am J Physiol. 1993;264:G868–73. [PubMed]
23. Song D, Liu H, Sharkey KA, Lee SS. Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology. 2002;35:159–66. [PubMed]
24. Li Y, Song D, Zhang Y, Lee SS. Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats. Gut. 2003;52:293–9. [PMC free article] [PubMed]
25. Liu H, Schuelert N, McDougall JJ, Lee SS. Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut. 2008;57:966–73. [PubMed]
26. Bayley TJ, Segel N, Bishop JM. The circulatory changes in patients with cirrhosis of the liver at rest and during exersize. Clin Sci. 1964;26:227–35. [PubMed]
27. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Circulation. 1974;49:755–60. [PubMed]
28. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial β-adrenergic receptors in cirrhotic rats. Hepatology. 1990;12:481–5. [PubMed]
29. Inglés AC, Hernαndez I, García-Estañ J, Quesada T, Carbonell LF. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol. 1991;260:H1912–7. [PubMed]
30. Fleming JW, Wisler PL, Watanabe AM. Signal transduction by G-protiens in cardiac tissues. Circulation. 1992;85:420–33. [PubMed]
31. Gilman AG. G-protiens: Transducers of receptor-generated signals. Annu Rev Biochem. 1987;56:615–49. [PubMed]
32. Reuter H. Calcium channel modulation by neurotransmitters, enzymes, and drugs. Nature. 1983;301:569–74. [PubMed]
33. Ma Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac beta- adrenergic receptor function in cirrhotic rats. Am J Physiol. 1994;267:G87–93. [PubMed]
34. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta -adrenergic receptor signalling in rats with cirrhoticcardiomyopathy. J Hepatol. 1997;26:904–12. [PubMed]
35. Jaue DN, Ma Z, Lee SS. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology. 1997;25:1361–5. [PubMed]
36. Le Grimellec C, Friedlander G, el Yandouzi EH, Zlatkine P, Giocondi MC. Membrane fluidity and transport properties in epithelia. Kidney Int. 1992;42:825–36. [PubMed]
37. Moreau R, Komeichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensetive potassium channels in rats with cirrhosis. Gastroenterology. 1994;106:1016–23. [PubMed]
38. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol. 1995;22:370–6. [PubMed]
39. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol. 1997;273:G537–44. [PubMed]
40. Smith TW, Balligand JL, Kaye DM, Wiviott SD, Simmons WW, Han X, et al. The role of the NO pathway in the control of cardiac function. J Card Fail. 1996;2:S141–7. [PubMed]
41. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: Pathogenic mechanisms. World J Gastroenterol. 2006;12:837–42. [PubMed]
42. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A. 1993;90:347–51. [PubMed]
43. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology. 2000;118:937–44. [PubMed]
44. Tohse N, Nakaya H, Takeda Y, Kanno M. Cyclic GMP-mediated inhibition of L-type Ca2+ channel activity by human natriuretic peptide in rabbit heart cells. Br J Pharmacol. 1995;114:1076–82. [PMC free article] [PubMed]
45. Liu H, Song D, Lee SS. Role of heme oxygenase - carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol Gastrointest Liver Physiol. 2001;280:G68–74. [PubMed]
46. Bonz A, Laser M, Küllmer S, Kniesch S, Babin-Ebell J, Popp V, et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol. 2003;41:657–64. [PubMed]
47. Ford WR, Honan SA, White R, Hiley CR. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol. 2002;135:1191–8. [PMC free article] [PubMed]
48. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol. 2005;146:315–23. [PMC free article] [PubMed]
49. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water-retention in cirrhosis. Hepatology. 1988;8:1151–7. [PubMed]
50. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis. 1986;6:287–98. [PubMed]
51. Arroyo V, Fernandez J, Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis. 2008;28:81–95. [PubMed]
52. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999;97:259–67. [PubMed]
53. Ruiz-del-Arbol L, Urman J, Fernαndez J, Gonzαlez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38:1210–8. [PubMed]
54. Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: A manifestation of cirrhotic cardiomyopathy? Hepatology. 2003;38:1089–91. [PubMed]
55. Villanueva C, Aracil C, Colomo A, Hernαndez-Gea V, López-Balaguer JM, Alvarez-Urturi C, et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology. 2009;137:119–28. [PubMed]
56. La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, García-Pagαn JC, et al. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol. 2009;51:279–87. [PubMed]
57. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923–8. [PubMed]
58. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52:742–8. [PubMed]
59. Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsen the hyperdynamic circulatory state of the cirrhotic patient: Preliminary report of a prospective study. Hepatology. 1994;19:129–32. [PubMed]
60. Rodríguez-Laiz JM, Bañares R, Echenagusia A, Casado M, Camuñez F, Pérez-Roldαn F, et al. Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results. Dig Dis Sci. 1995;40:2121–7. [PubMed]
61. Quiroga J, Sangro B, Núñez M, Bilbao I, Longo J, García-Villarreal L, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral and hemodynamic parameters. Hepatology. 1995;21:986–94. [PubMed]
62. Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: Short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999;29:632–9. [PubMed]
63. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS) Am J Gastroenterol. 2002;97:142–8. [PubMed]
64. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104:2458–66. [PubMed]
65. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut. 2007;56:869–75. [PMC free article] [PubMed]
66. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2000;6:S44–52. [PubMed]
67. Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation. 2009;87:763–70. [PubMed]
68. Ripoll C, Catalina MV, Yotti R, Olmedilla L, Pérez-Peña J, Lo Iacono O, et al. Cardiac dysfunction during liver transplantation: Incidence and preoperative predictors. Transplantation. 2008;85:1766–72. [PubMed]
69. Marquez J, Martin D, Virji MA, Kang YG, Warty VS, Shaw B, Jr, et al. Cardiovascular depression secondary to citrate intoxication during orthotropic liver transplantation in man. Anesthesiology. 1986;65:457–61. [PubMed]
70. Dec GW, Kondo N, Farrell ML, Dienstag J, Cosimi AB, Semigran MJ. Cardiovascular complications following liver transplantation. Clin Transplant. 1995;9:463–71. [PubMed]
71. Della Rocca G, Costa MG, Pompei L, Chiarandini P. The liver transplant recipient with cardiac disease. Transplant Proc. 2008;40:1172–4. [PubMed]
72. Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl. 2004;10:1441–53. [PubMed]
73. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation. 1996;61:1180–8. [PubMed]
74. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation. 2002;73:901–6. [PubMed]
75. Park SC, Beerman LB, Gartner JC, Zitelli BJ, Malatack JJ, Fricker FJ, et al. Echocardiographic findings before and after liver transplantation. Am J Cardiol. 1985;55:1373–8. [PubMed]
76. Nasraway SA, Klein RD, Spanier TB, Rohrer RJ, Freeman RB, Rand WM, et al. Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation: evidence for early postoperative myocardial depression. Chest. 1995;107:218–24. [PubMed]
77. Agusti AG, Roca J, Rodriguez-Roisin R, Mastai R, Wagner PD, Bosch J. Pulmonary hemodynamics and gas exchange during exercise in liver cirrhosis. Am Rev Respir Dis. 1989;139:485–91. [PubMed]
78. Rassiat E, Barrière E, Durand F, Bernuau J, Belghiti J, Valla D, et al. Pulmonary hemodynamics and gas exchange after liver transplantation in patients with cirrhosis. Dig Dis Sci. 2002;47:746–9. [PubMed]
79. Sogni P, Garnier P, Gadano A, Moreau R, Dall’Ava-Santucci J, Dinh-Xuan AT, et al. Endogenous pulmonary nitric oxide production measured from exhaled air is increased in patients with severe cirrhosis. J Hepatol. 1995;23:471–3. [PubMed]
80. Rolla G, Brussino L, Colagrande P, Scappaticci E, Morello M, Bergerone S, et al. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med. 1998;129:375–8. [PubMed]
81. Delclaux C, Mahut B, Zerah-Lancner F, Delacourt C, Laoud S, Cherqui D, et al. Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med. 2002;165:332–7. [PubMed]
82. Zhang J, Ling Y, Luo B, Tang L, Ryter SW, Stockard CR, et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology. 2003;125:1441–51. [PubMed]
83. Rolla G, Bucca C, Brussino L. Methylene blue in the hepatopulmonary syndrome. N Engl J Med. 1994;331:1098. [PubMed]
84. Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med. 2000;133:701–6. [PubMed]
85. Rolla G, Brussino L, Colagrande P, Dutto L, Polizzi S, Scappaticci E, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology. 1997;26:842–7. [PubMed]
86. Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: A new approach. Gastroenterology. 1998;114:305–10. [PubMed]
87. Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: Hepatopulmonary syndrome. J Clin Gastroenterol. 2005;39:S138–42. [PubMed]
88. Zhang HY, Han DW, Wang XG, Zhao YC, Zhou X, Zhao HZ. Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome. World J Gastroenterol. 2005;11:567–72. [PubMed]
89. Rabiller A, Nunes H, Lebrec D, Tazi KA, Wartski M, Dulmet E, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med. 2002;166:514–7. [PubMed]
90. Krowka MJ, Tajik AJ, Dickson ER, Wiesner RH, Cortese DA. Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates: Screening by two-dimensional contrast-enhanced echocardiography. Chest. 1990;97:1165–70. [PubMed]
91. Hedenstierna G, Söderman C, Eriksson LS, Wahren J. Ventilation-perfusion inequality in patients with non-alcoholic liver cirrhosis. Eur Respir J. 1991;4:711–7. [PubMed]
92. Ramsay MA. Portopulmonary hypertension and hepatopulmonary syndrome, and liver transplantation. Int Anesthesiol Clin. 2006;44:69–82. [PubMed]
93. Huffmyer JL, Nemergut EC. Respiratory dysfunction and pulmonary disease in cirrhosis and other hepatic disorders. Respir Care. 2007;52:1030–6. [PubMed]
94. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med. 1996;17:17–33. [PubMed]
95. Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med. 1996;17:151–69. [PubMed]
96. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363:1461–8. [PubMed]
97. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: Morphologic and clinical features. J Am Coll Cardiol. 1987;10:1233–8. [PubMed]
98. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67:737–44. [PubMed]
99. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001;345:325–34. [PubMed]
100. Davis HH, 2nd, Schwartz DJ, Lefrak SS, Susman N, Schainker BA. Alveolarcapillary oxygen disequilibrium in hepatic cirrhosis. Chest. 1978;73:507–11. [PubMed]
101. Krowka MJ, Cortese DA. Hepatoplumonary syndrome: Current concepts in diagnosis and therapeutic considerations. Chest. 1994;105:1528–37. [PubMed]
102. Krowka MJ, Cortese DA. Hepatopulmonary syndrome: An evolving perspective in the era of liver transplantation. Hepatology. 1990;11:138–42. [PubMed]
103. Hoffbauer FW, Rydell R. Multiple pulmonary arteriovenous fistulas in juvenile cirrhosis. Am J Med. 1956;21:450–60. [PubMed]
104. Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome: A liver-induced lung vascular disorder. N Engl J Med. 2008;358:2378–87. [PubMed]
105. Ferreira MA, Barreto SS, Knorst MM, Silva MR, Pinotti AF. Semiquantitative echocardiographic evaluation of intrapulmonary vascular dilatations: Correlation with evaluation of shunt levels and pulmonary function parameters. J Bras Pneumol. 2009;35:106–13. [PubMed]
106. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology. 2005;41:1122–9. [PubMed]
107. Lange PA, Stoller JK. The hepatopulmonary syndrome: Effect of liver transplantation. Clin Chest Med. 1996;17:115–23. [PubMed]
108. Philit F, Wiesendanger T, Gille D, Boillot O, Cordier JF. Late resolution of hepatopulmonary syndrome after liver transplantation. Respiration. 1997;64:173–5. [PubMed]
109. Mandell MS, Groves BM, Duke J. Progressive plexogenic pulmonary hypertension following liver transplantation. Transplantation. 1995;59:1488–90. [PubMed]
110. Abrams GA, Rose K, Fallon MB, McGuire BM, Bloomer JR, van Leeuwen DJ, et al. Hepatopulmonary syndrome and venous emboli causing intracerebral hemorrhages after liver transplantation: A case report. Transplantation. 1999;68:1809–11. [PubMed]
111. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl. 2005;11:1107–11. [PubMed]
112. Krowka MJ. Pulmonary hypertension, (high) risk of orthotopic liver transplantation, and some lessons from “primary” pulmonary hypertension (editorial) Liver Transpl. 2002;8:389–90. [PubMed]
113. Ramsay MA. Perioperative mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6:451–2. [PubMed]
114. Ramsay MA. Portopulmonary hypertension and hepatopulmonary syndrome, and liver transplantation. Int Anesthesiol Clin. 2006;44:69–82. [PubMed]
115. Al-Hamoudi W, Alqahtani S, Ma M, Lee SS. Hemodynamics in the immediate postoperative period after liver transplantation in alcoholic and postviral cirrhosis. Can J Gastroenterol. 2007;21:S029.
116. Glauser FL. Systemic hemodynamics and cardiac function changes in patients undergoing orthotropic liver transplantation. Chest. 1990;98:1210–5. [PubMed]
117. Navasa M, Feu F, García-Pagαn JC, Jiménez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology. 1993;17:355–60. [PubMed]
118. Henderson JM, Mackay GJ, Hooks M, Chezmar JL, Galloway JR, Dodson TF, et al. High cardiac output of advanced liver disease persists after orthotropic liver transplantation. Hepatology. 1992;15:258–62. [PubMed]
119. Gadano A, Hadengue A, Widmann JJ, Vachiery F, Moreau R, Yang S, et al. Hemodynamics after orthotropic liver transplantation: Study of associated factors and long-term effects. Hepatology. 1995;22:458–65. [PubMed]

Articles from Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association are provided here courtesy of Wolters Kluwer -- Medknow Publications